What is the main business of Biosynthesis?

The main business activity of Biosynthesis focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on September 18, 2015.

Where is the headquarters located?

The headquarters is located at: ul. Rubież 46H, 61-612 Poznań.

Who is on the management board?

The management board consists of: Marcin Krzysztof Chmielewski (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 50,000 (approx. $13,506).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What revenue was generated?

In 2025, the company generated total revenue of $2,379, representing a decrease of 67.0% compared to 2024.

Is the company profitable?

No, in 2025 the company was not profitable, reporting a net loss of $1,189. For comparison, in 2024 the loss was $3,244, meaning the company reduced its loss by 63.4%.

What is the main operating cost?

The largest operating cost category falls under external services. This category amounted to $1,431 in 2025, representing 44% of all operating expenses.

Biosynthesissp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2015-09-18

Share capital

50,000.00 PLN

Registered address

ul. Rubież 46H/229, 61-612 Poznań, Poland

Website

biosynthesis.pl

Financials

Revenue history (in k)

Filing timeliness

2 of 6 financial statements were filed late (the longest delay 79 days for 2021).

202516/07/2026
202411/07/2025
202315/07/2024
202215/07/2023
202102/10/2022
202003/10/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Industry · Research and experimental development on biotechnology306 / 386

Top 79%

Division · Scientific research and development1,626 / 1,952

Top 83%

Sector · Professional, scientific and technical activities34,844 / 39,180

Top 89%

City · Poznań10,565 / 11,746

Top 90%

Voivodeship · Wielkopolskie28,543 / 30,975

Top 92%

Country · Poland274,427 / 298,580

Top 92%

Results vs industry

Revenue

This companyUSD 2.38kMedianUSD 55.66kAverageUSD 2.70m

Net profit

This companyUSD -1.19kMedianUSD -1.27kAverageUSD -92.16k

Operating costs

This companyUSD 3.24kMedianUSD 65.85kAverageUSD 2.66m

Assets

This companyUSD 7.58kMedianUSD 133.19kAverageUSD 3.03m

Industry

Authorized Representatives

Marcin Krzysztof Chmielewskiage 56 – President of the Management Board

Manner of representation

In the event that a multi-member management board is appointed, two members of the management board acting jointly are authorized to make declarations of will on behalf of the company.

Ownership

Owner	Shares	Share value	Stake
Marcin Krzysztof Chmielewskiage 56	950	$12,830.90	95%
Others	50	$675.31	5%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2021-05-11.

mBank
47 1140 2004 0000 3502 7594 2932

Debt

No entries in the National Debtors Register (KRZ).

Public aid

Grant date	Purpose	Gross amount	Granting body
Jun 30, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$1,282$1,282	Starosta Powiatu Poznań

Competitors

Name	Revenue	Website
GenxoneS.A.	$665,361.35	genxone.eu
Polbiotech Laboratoriumsp. z o.o.	$645,943.81	polbiotech.pl
Relvosp. z o.o.	$120,693.26	relvo.pl
Microblicsp. z o.o.	$122,383.50	microblic.pl
Xenstatssp. z o.o.	$66,774.27	xenstats.com
Greenetoxsp. z o.o.	$3,013.95	greenetox.com
Passio Human Microbiomesp. z o.o.	$1,856.58	passiohumanmicrobiome.com
Fungotechsp. z o.o.	$187.68	fungo.tech
Dystrogen TherapeuticsS.A.	–	dystrogen.com
MIMO BiotechP.S.A.	–	mimobiotech.com

FAQ

Last updated: 2026-07-17